Wuhan General Group
M2Bio Sciences, a company that develops innovative healthcare solutions through cannabis and mushroom-based sciences, with focus on psilocybin and cannabinoids, targeting drug discovery and treatment sales in anxiety, depression, ADHD.
Launch date
Employees
Market cap
$5.5k
Enterprise valuation
$6k (Public information from Sep 2024)
Share price
$0.0001 WUHN
Reno Nevada (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
$450k | Post IPO Equity | ||
Total Funding | - |